大麻二酚治疗耐药性癫痫研究进展

扫码查看

原文链接

NETL
NSTL
万方数据

中文摘要：全球约7 000万人罹患癫痫,在我国癫痫患者约1 000万例.癫痫的一线治疗方案为使用抗癫痫发作药物,尽管目前不断有抗癫痫药物获批上市,然而癫痫耐药患者人数仍占癫痫患者总人数的30％.大麻二酚(cannabidiol,CBD)是一种天然存在的具有抗癫痫特性的大麻素,临床研究结果表明CBD对Dravet综合征、Lennox Gastaut综合征、结节性硬化性癫痫等耐药性癫痫取得了良好的治疗效果,其作用机制广泛,安全性良好,已获得美国FDA批准上市.本文总结了耐药性癫痫发病机制和CBD治疗不同类型耐药性癫痫的疗效、机制和安全性,为临床进一步了解CBD提供参考.

外文标题：Advances in the treatment of drug-resistant epilepsy with cannabidiol

外文摘要：There are approximately 70 million people suffering from epilepsy around the world with about 10 million epilepsy patients in China.The main treatment of epilepsy is anti-seizure medicine.Despite the continuous development of these drugs,around 30％of epilepsy patients still experience drug resistance.Cannabidiol(CBD)is a natural cannabinoid that has been found anti-epileptic properties.Clinical studies have shown that CBD is effective in treating drug-resistant epilepsy,including conditions such as Dravet syndrome,Lennox Gastaut syndrome,and tuberous sclerosis epilepsy.CBD has a wide range of action mechanism and is considered safe,thus it has been approved by the US Food and Drug Administration.This article provides a summary of the pathogenesis of drug-resistant epilepsy,the efficacy,the mechanism,and safety of CBD in treating different types of drug-resistant epilepsy,aiming to provide epilepsy specialists with a reference to enhance their understanding of CBD.

外文关键词：

epilepsydrug-resistant epilepsycannabidiolDravet syndromeLennox-Gastaut syndromtuberous sclerosing

作者：

王继芬、叶兰、冯占辉

展开 >

作者单位：

贵州医科大学附属医院神经内科,贵阳 550004

兴义市人民医院神经内科,兴义 562400

贵州医科大学基础医学院,贵阳 550004

关键词：

癫痫耐药性癫痫大麻二酚 Dravet综合征 Lennox-Gastaut综合征结节性硬化

基金：

国家自然科学基金资助项目国家自然科学基金资助项目贵州省科技厅资助项目贵州省科技厅资助项目

项目编号：

8196022482360266黔科合基础-ZK[2023]一般395黔科合基础-ZK[2023]一般324

出版年：

2024

中国新药杂志

中国医药科技出版社中国医药集团总公司中国药学会

中国新药杂志

CSTPCD北大核心

影响因子：1.039

ISSN：1003-3734

年,卷(期)：2024.33(19)